Weekly Digest – May 2026 Weekly Digest – May 2026 29 April 2026: The NMPA has granted BTD for B7-H3-targeted ADC HS-20093 for castration-resistant prostate cancer Hansoh Pharmaceutical announced that China’s National Medical Products Administration has granted Breakthrough Therapy designation […]
Weekly Digest – May 2026 Weekly Digest – May 2026 30 April 2026: Alphamab Oncology announces IND application for TROP2/HER3 bispecific ADC JSKN016SC officially accepted by CDE Alphamab Oncology announced that the IND application for its TROP2/HER3 bispecific antibody–drug conjugate […]
Weekly Digest – May 2026 Weekly Digest – May 2026 28 April 2026: Taiho Pharmaceutical and Araris Biotech AG advance ADC ARC-02 into phase 1 clinical development Taiho Oncology, Taiho Pharmaceutical, and Araris Biotech announced that the U.S. FDA has […]
Weekly Digest – May 2026 Weekly Digest – May 2026 29 April 2026: SYS6051 obtains clinical trial approval in the U.S. CSPC Pharmaceutical Group announced that the U.S. FDA has approved the Investigational New Drug application for its antibody drug […]
Weekly Digest – May 2026 Weekly Digest – May 2026 24 April 2026: Novartis withdraws EMA application for adding new indication for Pluvicto Novartis announced that it has withdrawn its Type II variation application with the European Medicines Agency for […]
Weekly Digest – May 2026 Weekly Digest – May 2026 29 April 2026: Tacalyx secures €11 million to advance lead TACA-targeting ADC programme toward the clinic Tacalyx announced the selection of its first clinical candidate, TCX-201, an antibody drug conjugate […]
